Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Crizotinib vs Chemotherapy in First-Line ALK+ NSCLC
NCT01154140Phase 3Completed
- Sponsor
- Pfizer
- Start
- Jan 2011
- Primary completion
- Nov 2013
- Modality
- Small Molecules
- Countries
- 31
01
Overview
A Phase 3 trial of crizotinib in non-small cell lung cancer (NSCLC), sponsored by Pfizer. Started Jan 2011; status: completed.
02
Drugs
crizotinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT01154140.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01154140.